Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot shows promise against tough lung cancer

NCT ID NCT06883630

Disease control Sponsor: RemeGen Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental drug called RC148, given as an injection, in people with advanced non-small cell lung cancer that has spread. The study looks at how well the drug shrinks tumors, either alone or combined with other treatments. About 121 adults aged 18-80 with good performance status are enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

121 people

The number who actually took part.

Started

Mar 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntarily participate in the study and signed the ICF; 2. Be willing to and able to act on the trial and the follow up procedures; 3. Male or female, aged 18-80 years; 4. Expected survival ≥ 3 months; 5. ECOG PS score 0 or 1; 6. All participants to be enrolled in cohorts 1-5 must be diagnosed with histopathologically or cytologically confirmed, unresectable locally advanced or metastatic NSCLC (stage IIIB//IIIC/IV according to the 8th edition of UICC/AJCC) and not amendable to curative surgery or radiation as assessed by investigator. Exclusion Criteria: 1. Histopathologically or cytologically confirmed small cell lung cancer; 2. Received major surgeries and still in recovery within 28 days before the first dose; 3. Received any live vaccine within 28 days prior to the first dose or plan to be vaccinated during the study (except for COVID-19 vaccine); 4. Received immune checkpoint inhibitor (anti-PD-1/PD-L1/CTLA-4 antibody) or other immune checkpoint inhibitor treatment within 28 days prior to the first dose, or experienced prior permanent immunotherapy discontinuation due to immunotoxicity; 5. Participated in other clinical trials and received other investigational anti-tumor therapy within 28 days prior to the first dose; 6. Poor compliance and unable to complete the study procedures as assessed by investigator; 7. Have any other medical conditions, abnormal physical examinations or laboratory examinations that would be suspected interfere with participation or evaluation of the trial or increase the risk to the participant, in view of the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Affiliated Cancer Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Beijing Tiantan Hospital of Capital Medical University

    Beijing, Beijing Municipality, China

  • Binzhou Medical University Hospital

    Binzhou, Shandong, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan cancer hospital

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • Nanyang Second General Hospital

    Hanyang, Henan, China

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shunde Hospital of Southern Medical University

    Foshan, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • The First Affiliated Hospital of Xinxiang Medical College

    Xinxiang, Henan, China

  • The First People's Hospital of Shunde

    Foshan, Guangdong, China

  • The First affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Guilin Medical College

    Gulin, Guangxi, China

  • Tianjin Medical University Cancer Institute Hospital

    Tianjin, Tianjin Municipality, China

  • Union Hospital Tongji Medical College Huazhong University Of Science And Technologe

    Wuhan, Hubei, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.